Fig. 5

Higher tumor and blood monocyte/lymphocyte ratio in non-responders. a Peripheral lymphocyte counts from left to right at baseline, cycle 1, cycle 2, and cycle 3, according to the response group (blue: ‘Progressive’ group; yellow: ‘Stable+Elite’ group). Mean ± 95%CI, Kolmogorov–Smirnov test. b Monocyte/lymphocyte ratio (MonoLR) computed on blood values (monocyte absolute count/lymphocyte absolute count) from left to right at baseline, cycle 1, cycle 2, and cycle 3, according to the response group. Mean ± 95%CI, Kolmogorov–Smirnov test. c Tumor monocytic-lineage/lymphocyte ratio (MonoLR_tumor) obtained from RNAseq data with CIBERSORTabs and EPIC, according to the response group. Mean ± 95%CI, Kolmogorov–Smirnov test. d Correlation plot between blood MonoLR (x-axis) and tumor MonoLR values by EPIC (y-axis). Blue crosses refer to progressive patients while yellow crosses refer to patients with stable or responsive disease. The dotted line fits with the simple linear regression of equation Y = 0.3401*X−0.07988. e and f Kaplan–Meier curves of progression-free survival (PFS, e) and overall survival (f) from left to right: using baseline blood MonoLR in the training cohort, using baseline blood MonoLR in the validation cohort, and using baseline tumor MonoLR as estimated by the EPIC algorithm. Black lines refer to patients with baseline MonoLR < indicated threshold whereas green lines refer to patients with baseline MonoLR ≥ threshold. Logrank hazard ratio and P-values are depicted